Anest. intenziv. Med. 2017;28(2):101-105

Inhalational application of furosemide - the breathlessness panacea?Case Report

R. Škulec
1 Klinika anesteziologie, perioperační a intenzivní medicíny, Univerzita J. E. Purkyně v Ústí nad Labem Masarykova nemocnice v Ústí nad Labem
2 Zdravotnická záchranná služba Středočeského kraje, Kladno
3 Klinika anesteziologie a intenzivní medicíny, Univerzita Karlova, Lékařská fakulta v Hradci Králové, Fakultní nemocnice Hradec Králové
4 Centrum pro výzkum a vývoj, Univerzita Karlova, Lékařská fakulta v Hradci Králové, Fakultní nemocnice Hradec Králové

Dyspnoea is a serious symptom requiring causal and/or palliative management in a variety of acute and chronic clinical conditions. It has been shown that inhaled furosemide (IAF) has the potential to be a new effective approach to dyspnoea management in a number of indications. This route of administration exerts significant bronchodilatation, relieves dyspnoea by suppressing the afferentation to the central nervous system and has a minimum diuretic effect. The author summarizes our current knowledge about the use of IAF in bronchial asthma, chronic obstructive pulmonary disease, heart failure and in the palliative treatment of dyspnoea, and presents a case report series in this article.

Keywords: inhaled furosemide; dyspnoea

Received: January 21, 2016; Accepted: November 12, 2016; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škulec R. Inhalational application of furosemide - the breathlessness panacea? Anest. intenziv. Med. 2017;28(2):101-105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Greger, R., Wangemann, P. Loop diuretics. Ren. Physiol., 1987, 10, 3-4, p. 174-183. Go to original source... Go to PubMed...
    2. Nishino, T., Ide, T., Sudo, T., Sato, J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am. J. Respir. Crit. Care Med., 2000, 161, 6, p. 1963-1967. Go to original source... Go to PubMed...
    3. Nishino, T. Dyspnoea: Underlying mechanisms and treatment. Br. J. Anaesth., 2011, 106, 4, p. 463-474. Go to original source... Go to PubMed...
    4. Jensen, D., Amjadi, K., Harris-McAllister, V., Webb, K. A., O'Donnell, D. E. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax, 2008, 63, 7, p. 606-613. Go to original source... Go to PubMed...
    5. Nishino, T. Pathophysiology of dyspnea evaluated by breath-holding test: studies of furosemide treatment. Respir. Physiol. Neurobiol., 2009, 167, 1, p. 20-25. Go to original source... Go to PubMed...
    6. Sudo, T., Hayashi, F., Nishino, T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am. J. Respir. Crit. Care Med., 2000, 162, 3, p. 971-975. Go to original source... Go to PubMed...
    7. Undem, B. J. The Role of Vagal Afferent Nerves in Chronic Obstructive Pulmonary Disease. Proc. Am. Thorac. Soc., 2005, 2, 4, p. 355-360. Go to original source... Go to PubMed...
    8. Sant'Ambrogio, G., Widdicombe, J. Reflexes from airway rapidly adapting receptors. Respir. Physiol., 2001, 125, 1-2, p. 33-45. Go to original source... Go to PubMed...
    9. Lee, L. Y., Pisarri, T. E. Afferent properties and reflex functions of bronchopulmonary C-fibers. Respir. Physiol., 2001, 125, 1-2, p. 47-65. Go to original source... Go to PubMed...
    10. Niven, A. S., Argyros, G. Alternate treatments in asthma. Chest, 2003, 123, 4, p. 1254-1265. Go to original source... Go to PubMed...
    11. Corboz, M. R., Ballard, S. T., Gao, H. et al. Differential effects of furosemide on porcine bronchial arterial and airway smooth muscle. J. Appl. Physiol., 2000, 89, 4, p. 1360-1364. Go to original source... Go to PubMed...
    12. Saitoh, Y., Sasaki, F., Sakai, T. et al. Effects of inhaled furosemide after indomethacin premedication on bronchial hyperresponsiveness in patients with chronic congestive heart failure. Nihon. Kyobu. Shikkan. Gakkai. Zasshi., 1994, 32, 5, p. 413-417. Go to PubMed...
    13. Bhure, U. N., Bhure, S. U., Bhatt, B. M. et al. Lung epithelial permeability and inhaled furosemide: added dimensions in asthmatics. Ann. Nucl. Med., 2009, 23, 6, p. 549-557. Go to original source... Go to PubMed...
    14. Newton, P. J., Davidson, P. M., Krum, H., Ollerton, R., Macdonald, P. The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure. Heart. Lung. Circ., 2012, 21, 5, p. 260-266. Go to original source... Go to PubMed...
    15. Cavaliere, F., Masieri, S. Furosemide protective effect against airway obstruction. Curr. Drug. Targets., 2002, 3, 3, p. 197-201. Go to original source... Go to PubMed...
    16. Bianco, S., Pieroni, M. G., Refini, R. M., Rottoli, L., Sestini, P. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N. Engl. J. Med., 1989, 321, 16, p. 1069-1073. Go to original source... Go to PubMed...
    17. Munyard, P., Chung, K. F., Bush, A. Inhaled frusemide and exercise-induced bronchoconstriction in children with asthma. Thorax, 1995, 50, 6, p. 677-679. Go to original source... Go to PubMed...
    18. Seidenberg, J., Dehning, J., von der Hardt, H. Inhaled frusemide against cold air induced bronchoconstriction in asthmatic children. Arch. Dis. Child., 1992, 67, 2, p. 214-217. Go to original source... Go to PubMed...
    19. Inokuchi, R., Aoki, A., Aoki, Y., Yahagi, N. Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis. Crit. Care, 2014, 18, 6, p. 1-6. Go to original source... Go to PubMed...
    20. Hinckley, J. Inhaled furosemide in the treatment of acute exacerbations of asthma. Acad. Emerg. Med., 2000, 7, 10, p. 1167.
    21. Uronis, H. E., Currow, D. C., Abernethy, A. P. Palliative management of refractory dyspnea in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2006, 1, 3, p. 289-304. Go to original source... Go to PubMed...
    22. Kallet, R. H. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir. Care, 2007, 52, 7, p. 900-910.
    23. Ong, K. C., Kor, A. C., Chong, W. F., Earnest, A., Wang, Y. T. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2004, 169, 9, p. 1028-1033. Go to original source... Go to PubMed...
    24. Sheikh Motahar Vahedi, H., Mahshidfar, B., Rabiee, H. et al. The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial. Respir. Care, 2013, 58, 11, p. 1873-1877. Go to original source... Go to PubMed...
    25. Shimoyama, N., Shimoyama, M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J. Pain. Symptom. Manage., 2002, 23, 1, p. 73-76. Go to original source... Go to PubMed...
    26. Kohara, H., Ueoka, H., Aoe, K. et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J. Pain. Symptom. Manage, 2003, 26, 4, p. 962-967. Go to original source... Go to PubMed...
    27. Wilcock, A., Walton, A., Manderson, C. et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax, 2008, 63, 10, p. 872-875. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.